Overview

Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine (LdT) against continued lamivudine treatment. Results from patients who were taking lamivudine and then switched to telbivudine will be compared with the results from patients who continued on lamivudine alone.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Collaborator:
Novartis Pharmaceuticals
Treatments:
Lamivudine
Telbivudine